Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 4/20 | 0.61 |
| ▸ | DRD2 | P14416 | 4/20 | 0.61 |
| ▸ | HTR2A | P28223 | 4/20 | 0.61 |
| ▸ | DRD3 | P35462 | 4/20 | 0.61 |
| ▸ | DRD1 | P21728 | 3/20 | 0.61 |
| ▸ | DRD5 | P21918 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | USP2 | O75604 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.56 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.56 |
| ▸ | HRH1 | P35367 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8693302 | 0.93 | LTA4H (0.60) | HTR1ADRD2HTR2ADRD3DRD1 | |
| SCHEMBL8689920 | 0.85 | TMEM97 (0.72) | HTR1ADRD2HTR2ADRD3HRH3 | |
| SCHEMBL7397226 | 0.85 | HRH3 (0.65) | HTR1ADRD2HTR2ADRD3DRD1 | |
| Hydrochloric Acid SCHEMBL8694237 | 0.84 | TMEM97 (0.70) | HTR1ADRD2HTR2ADRD3HRH3 | |
| Hydrochloric Acid SCHEMBL8055586 | 0.84 | HRH3 (0.64) | HTR1ADRD2HTR2ADRD3DRD1 | |
| Hydrochloric Acid SCHEMBL7295872 | 0.83 | TMEM97 (0.69) | HTR1ADRD2HTR2ADRD3DRD1 | |
| SCHEMBL1728918 | 0.83 | USP2 (0.78) | HTR1ADRD2HTR2ADRD3DRD1 | |
| SCHEMBL24324269 | 0.82 | USP2 (0.68) | HTR1ADRD2HTR2ADRD3DRD1 | |
| SCHEMBL5568449 | 0.82 | HTR1A (0.50) | HTR1ADRD2HTR2ADRD3DRD1 | |
| SCHEMBL8690689 | 0.82 | LTA4H (0.57) | HTR1ADRD2HTR2ADRD3DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6908922-B2 | Anticholesterol agents; cardiovascular disorders | LES LABORATOIRES SERVIER (FR) | 2005-06-21 | — | — | US | disclosed |
| US-6903103-B2 | Linear cyclic ureas | LES LABORATORIES SERVIER (FR) | 2005-06-07 | — | — | US | disclosed |
| US-6780868-B2 | TREATMENT OF MYOCARDIAL OR PERIPHERAL ISCHAEMIA, CARDIAC INSUFFICIENCY OR PULMONARY ARTERIAL HYPERTENSION | LES LABORATOIRES SERVIER (FR) | 2004-08-24 | — | — | US | disclosed |
| US-20030229100-A1 | New linear cyclic ureas | PEGLION JEAN-LOUIS (FR) | 2003-12-11 | — | — | US | disclosed |
| US-20030225105-A1 | New linear cyclic ureas | PEGLION JEAN-LOUIS (FR) | 2003-12-04 | — | — | US | disclosed |
| US-20030191132-A1 | New linear cyclic ureas | PEGLION JEAN-LOUIS (FR) | 2003-10-09 | — | — | US | disclosed |
| US-6566364-B2 | Isomers, hydrates, solvates and addition salts in treatment of endothelial dysfunction disease such as atherosclerosis, dyslipidaemia; antidiabetic agents; heart transplantation; inhibition of nitrogen monoxide synthase and oxidative stress | LES LABORATOIRES SERVIER (FR) | 2003-05-20 | — | — | US | disclosed |
| EP-1113014-A1 | Linear or cyclic ureas, a process for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 2001-07-04 | — | — | EP | disclosed |
| EP-0526342-B1 | Isoquinolin-5yl-sulphonamides, process for their preparation and pharmaceutical compositions containing them | ADIR (FR) | 1996-12-04 | — | — | EP | disclosed |
| US-5208243-A | Analgesics | ADIR ET COMPAGNIE (FR) | 1993-05-04 | — | — | US | disclosed |
| EP-0526342-A1 | Isoquinolin-5yl-sulphonamides, process for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 1993-02-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191132-A1 | New linear cyclic ureas | GUCY1B1, UACA, GUCY1A1 | HTR1A 1186/4885DRD2 3284/4885HTR2A 2171/4885 |
| US-20030229100-A1 | New linear cyclic ureas | GUCY1B1, UACA, GUCY1A1 | HTR1A 1186/4885DRD2 3284/4885HTR2A 2171/4885 |
| US-20030225105-A1 | New linear cyclic ureas | GUCY1B1, UACA, GUCY1A1 | HTR1A 1186/4885DRD2 3284/4885HTR2A 2171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.